Daridorexant

if you want a modern sleep drug that works by turning down the brain's wake signal instead of sedating you like a benzo or a z-drug, daridorexant is the cleanest of the three approved orexin blockers on paper; ~8 hour half-life, real phase 3 data on both nighttime sleep and next-day functioning, and it is a schedule iv controlled substance so it is prescription-only.

generally well tolerated; in the phase 3 program the overall adverse-event rate at 25 mg and 50 mg was close to placebo, and the most common events were nasopharyngitis and headache (mignot 2022). the class-relevant signals to know: next-morning somnolence (dose-related, much lower than older hypnotics because of the short half-life), and rare orexin-class effects tied to the fact that absent orexin signaling is the biology of narcolepsy; sleep paralysis, vivid/hypnagogic hallucinations, and rare cataplexy-like muscle weakness. driving/next-day impairment risk is lower than z-drugs but not zero, especially at 50 mg. it is a schedule iv controlled substance (low but real abuse potential). avoid combining with alcohol or other cns depressants; use caution with strong cyp3a4 inhibitors (daridorexant is a cyp3a4 substrate) and in significant hepatic impairment. not for people with narcolepsy. long-term japanese data out to 52 weeks showed sustained benefit without new safety issues (uchimura 2024).

Daridorexant undergoes hepatic metabolism via CYP3A4. In a controlled study combining daridorexant 50 mg with citalopram at steady state, there were no clinically relevant pharmacokinetic interactions between the two drugs ^[6]. However, co-administration of daridorexant with strong CYP3A4 inhibitors such as ketoconazole or erythromycin requires dose reduction guidance, as these inhibitors will raise daridorexant exposure ^[7]. The pharmacokinetic mechanism is straightforward; inhibitors slow daridorexant's metabolism. Data on interactions with moderate CYP3A4 inhibitors and on induction effects remain scarce, and no pharmacodynamic interactions with other CNS-active agents have been systematically studied.

Checking a whole stack? Run it through interactions + stacks.

discovered at actelion and developed by its spin-out idorsia in switzerland; the discovery program leaned hard on physiology-based pharmacokinetic modeling to hit a specific brain-exposure and half-life target rather than just maximizing potency (treiber 2017). it cleared two large phase 3 trials in 2018-2020 (mignot 2022, lancet neurology) and was approved by the fda in january 2022 and by the ema shortly after, marketed as quviviq; it is the third DORA to market after suvorexant (2014) and lemborexant (2019). the early proposed inn 'nemorexant' was dropped in favor of daridorexant.

widely seen as the best-designed of the three approved orexin antagonists specifically because of its short half-life and its phase 3 evidence on daytime functioning, not just nighttime sleep numbers; sleep specialists like that it is a validated, non-sedative-hypnotic option for chronic insomnia. it is expensive and controlled, so in practice it competes with cheaper generics; but among the orexin drugs it has the strongest 'clean next day' story.